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Parkinson’s disease (PD) is a neurodegenerative disorder caused by loss of dopaminergic 
and serotoninergic signalling. A number of pathogenic mechanisms have been implicated 
including loss of mitochondrial function at the level of complex I, and lysosomal metabolism 
at the level of lysosomal glucocerebrosidase (GBA1). In order to investigate further the 
potential involvement of complex I and GBA1 in PD, we assessed the impact of loss of 
respective enzyme activities upon dopamine and serotonin turnover. Using SH-SY5Y cells, 
complex I deficiency was modelled by using rotenone whilst GBA1 deficiency was modelled 
by the use of conduritol B epoxide (CBE). Dopamine, its principal metabolites, and the 
serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the extracellular medium were 
quantified by HPLC. Inhibition of complex I significantly increased extracellular 
concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-HIAA. Comparable results 
were observed with CBE. These results suggest increased monoamine oxidase activity and 
provide evidence for involvement of impaired complex I or GBA1 activity in the 
dopamine/serotonin deficiency seen in PD. Use of extracellular media may also permit 
relatively rapid assessment of dopamine/serotonin metabolism and permit screening of 
novel therapeutic agents. 
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Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder of 
dopaminergic neurons with characteristic symptoms that include tremor, rigidity and 
bradykinesia. Despite the considerable research that has been carried out in this field, the 
primary cause of PD is still unknown. Consequently, current therapies provide a temporary 
symptomatic relief by aiming to increase dopamine availability. These treatments vary 
depending on the stage of the disease, but gold standard treatment for PD is the dopamine 
precursor L-dihydroxyphenylalanine (L-DOPA) along with inhibitors of the dopamine 
degradation enzymes (Birkmayer et al., 1975). 
Concerning putative mechanisms, loss of brain mitochondrial complex I activity has been 
reported in patients with PD (Schapira et al., 1990). Observations relating to the 
parkinsonian features associated with  exposure to complex I inhibitors, such as rotenone 
and MPP+, provide credence for deficiency of complex I being a factor in PD. (Dauer and 
Przedborski, 2003). With regards to the consequences of reduced complex I activity, a 
number of mechanisms have been proposed, including reduced ATP formation and 
oxidative stress.  
Neuronal complex I activity appears to exert particular control over mitochondrial ATP 
formation and losses of activity comparable to those seen in PD can be expected to lead to 
compromised brain energy metabolism (Davey and Clark, 1996). Furthermore, in the 
presence of oxidative stress, the magnitude of complex I loss required to inhibit ATP 
generation is significantly less (Davey et al., 1998). Oxidative stress occurs as a result of 
excessive generation of oxidising molecules, such as reactive oxygen and nitrogen species, 
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and/or loss of antioxidant capacity for scavengers such as alpha-tocopherol, ascorbate and 
reduced glutathione (GSH; Barker et al., 1996; Bolanos et al., 1995; Riederer et al., 1989). 
Inhibition of the mitochondrial respiratory chain is associated with increased generation of 
reactive oxygen species, a situation that appears to precede impairment of energy 
metabolism (Jacobson et al., 2005). 
With regards to antioxidant status, decreased GSH levels have been reported in the brain of 
patients with PD (Perry et al., 1982; Sian et al., 1994). Furthermore, comparable losses have 
been reported in patients deemed to have pre-symptomatic PD (Jenner et al., 1992). 
Although GSH levels in the pre-PD patients are decreased to comparable level to those seen 
in PD, it is of note that complex I activity was not decreased (Jenner et al., 1992). This raises 
the possibility that GSH loss precedes and contributes to the loss of complex I activity, a 
hypothesis that is supported by a number of observations in both cellular and animal 
models (Barker et al., 1996; Bolanos et al., 1996; Heales et al., 1994; Heales et al., 2011). 
Another potential mechanism implicated in PD pathogenesis is failure of lysosomal 
autophagy (Lynch-Day et al., 2012) leading to impaired protein processing, e.g. alpha-
synuclein and formation of Lewy bodies that  are characteristic of PD (Beyer, 2007). In post 
mitotic neurons, this failure of autophagy may also lead to the accumulation of defective 
mitochondria and provides a further potential mechanism for the compromised 
mitochondrial function in PD. Support for lysosomal involvement in PD comes from the 
study of patients with either homozygous mutations (Gaucher disease) or heterozygous 
mutations in lysosomal glucocerebrosidase (GBA1). Such individuals have a significantly 
increased risk of developing PD (Neumann et al., 2009). A number of mechanisms have been 
proposed to link the increased risk of PD with impairment of GBA1. Amongst these are 
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aberrant alpha-synuclein processing, oxidative stress and mitochondrial defects including 
loss of mitochondrial respiratory chain activity (Cleeter et al., 2013; Mazzulli et al., 2011; 
Osellame et al., 2013; Sidransky and Lopez, 2012). The link between PD and loss of GBA1 
activity is further evidenced by reports of altered dopamine metabolites in CSF of patients 
with Gaucher/PD (Alonso-Canovas et al., 2010; Machaczka et al., 2012). In such studies, 
compromised serotonin metabolism was also implicated. 
In view of the fact that loss of dopaminergic neurons is the ultimate consequence for all the 
possible mechanisms considered in PD, its metabolism will be briefly reviewed. Serotonin 
metabolism will also be considered, due to the possible involvement of this 
neurotransmitter in PD (Olivola et al., 2014) and the clear overlap between dopamine and 
serotonin metabolism. 
Synthesis of dopamine commences with the transformation of the amino acid L-tyrosine 
into L-DOPA by the tetrahydrobiopterin (BH4)-dependent tyrosine hydroxylase (TH). This is 
then converted by aromatic amino acid decarboxylase (AADC), a pyridoxal phosphate (PLP) 
requiring enzyme, to dopamine [Fig 1]. L-DOPA that is not metabolised via AADC can be 
converted to 3-O-methyldopa (3-OMD) via catechol-O-methyl transferase (COMT) [Fig 1]. As 
dopamine is not stable at physiological pH, it is internalised and stored in synaptic vesicles 
by vesicular monoamine transporter 2 (VMAT2; Chaudhry et al., 2008). This transporter uses 
a proton gradient generated by the vacuolar-type ATPase proton pump. In these vesicles the 
pH is two units lower than in the cytosol, so dopamine does not spontaneously oxidise 
(Guillot and Miller, 2009). It has been proposed that TH, AADC and VMAT2 interact forming 
a complex to make dopamine internalisation in vesicles as efficient as possible (Cartier et al., 
2010). When acting as a neurotransmitter, dopamine is released into the synaptic cleft and 
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binds to receptors. After its release, dopamine is removed from the synaptic cleft by the 
pre-synaptic neuronal terminal cells which capture the dopamine via the dopamine 
transporter (DAT; reviewed by Eriksen et al., 2010). The internalised dopamine can be either 
recycled or degraded. For recycling, dopamine is sequestered into synaptic vesicles by 
VMAT2. The non-recycled neurotransmitter is further metabolised via two parallel 
pathways. In the first route, monoamine oxidase (MAO) and aldehyde dehydrogenase 
(ALDH) metabolise dopamine to 3,4-dihydroxyphenylacetic acid (DOPAC). Then, DOPAC is 
subsequently converted to homovanillic acid (HVA) by COMT. In the second route, COMT 
first transforms dopamine to 3-methoxytyramine (3-MT). HVA is then formed by the 
consecutive action of MAO and ALDH [Fig 1]. 
Dopamine metabolism is closely related to serotonin synthesis and degradation, because 
both pathways share some enzymes [Fig 1]. Serotonin synthesis starts with the oxidation of 
L-tryptophan by tryptophan hydroxylase (TPH) and the cofactor BH4. This reaction is the 
rate limiting step in this pathway and produces 5-hydroxytryptophan (5-HTP). 5-HTP is 
decarboxylated by AADC with PLP as cofactor, synthesising serotonin. As with dopamine, 
serotonin has to be quickly degraded after its action. To accomplish this, MAO and ALDH 
transform serotonin into 5-hydroxyindoleacetic acid (5-HIAA), its final degradation 
metabolite. 
In view of the clear link between PD and loss of mitochondrial and lysosomal function, in 
this study we have examined the effects of loss of complex I or GBA1 upon dopamine and 
serotonin metabolism. Extracellular media was evaluated to ascertain whether relatively 




2. Materials and methods 
2.1. Materials 
All the chemicals were supplied by Sigma Aldrich (Poole, UK), Thermo Fisher Scientific UK 
Ltd (Loughborough, UK) and VWR International Ltd (Lutterworth, UK). C18HS column, 250 
mm × 4.6 mm with a pore size of 100A and a particle size of 5um, was purchased from 
Kromatek (Dunmow, UK).  
2.2. Tissue culture and L-DOPA treatment 
Undifferentiated SH-SY5Y cells obtained from the European Collection of Cell Cultures 
(Public Health England, Salisbury, UK) were used in this study, as they have been widely 
used for PD research (Alberio et al., 2014; Hong-rong et al., 2010; Khwanraj et al., 2015; 
Lopes et al., 2010; Noelker et al., 2015). SH-SY5Y cells between passage 21 and 24 were 
seeded at a density of 6×103 cells/cm2 with DMEM/F-12 supplemented with 10% FBS and 2 
mM L-glutamine. Cells were grown at 37°C in a 5% CO2 incubator. On day 6 after seeding, 
SH-SY5Y cells were treated with rotenone at concentration of 100 nM (Aylett et al., 2013). In 
parallel, SH-SY5Y cells were seeded in supplemented DMEM/F-12 media containing 100 μM 
conduritol B-epoxide (CBE), a selective and irreversible GBA1 inhibitor. On day 7 after 
seeding, the cells were exposed to L-DOPA, the immediate precursor of dopamine, to assess 
dopamine metabolism [Fig 1] (Woodard et al., 2014). SH-SY5Y cells were treated for 1 hour 
with 100 μM L-DOPA in DMEM/F-12 phenol red free media, supplemented with 10% of FBS. 
Media was collected and mixed with perchloric acid to a final concentration of 0.4 M. 
Samples were incubated for 10 min at 4°C in the dark and centrifuged at 12000×g for 5 min 
at 4°C. Supernatant was collected and analysed by high performance liquid chromatography 
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(HPLC) coupled to an electrochemical detector. The appearance of dopamine and its 
metabolites in the cell culture medium was considered as a reflection of cellular dopamine 
metabolism. To assess serotonin turnover, the MAO product 5-HIAA was also quantified in 
the cell culture medium. 
In order to confirm that L-DOPA was being converted to dopamine through AADC, cells were 
incubated with 10 μM 3-hydroxybenzylhydrazine dihydrochloride (NSD-1015) for 24 hours 
before L-DOPA treatment. 
 
2.3. High performance liquid chromatography 
Dopamine, 3-OMD, HVA, DOPAC and 5-HIAA were quantified using reverse-phase HPLC with 
an electrochemical detector, following the method of Allen et al. (2013) with some 
modifications for the contemporary detection of all five compounds. The stationary phase 
was maintained at 27°C. The mobile phase (flow rate of 1.5 ml/min) was aqueous with 16% 
methanol, 20 mM sodium acetate trihydrate (pH 3.45), 12.5 mM citric acid monohydrate, 
0.1 mM EDTA sodium and 3.35 mM 1-octanesulfonic acid. 50 µl of each sample were 
injected into the system. At voltage of 450 mV for the detector electrode and 20 mV for the 
screening electrode, sample quantification was calculated against an external standard 
mixture of 500 nM of all five compounds made in ultrapure water with few drops of 12 M 
hydrochloric acid. Peak area from the electrochemical detector was quantified with 





2.4. GBA1 Activity 
GBA1 activity was measured using the synthetic substrate 4-methylumbelliferone-b-
glucopyranoside as previously described (Burke et al., 2013). 
2.5. Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). Between 5 and 16 
independent cell culture preparations were utilised. Individual comparisons of means were 
made using unpaired Student’s t-test and multiple comparisons of means was made using 
one-way ANOVA followed by Tukey’s post hoc test using GraphPad Prism software 




In the absence of L-DOPA treatment, it was not possible to detect dopamine and its 
metabolites in the cell culture medium (data not shown). However, treatment with L-DOPA 
for 1 hour permitted clear quantification [Fig 2]. NSD-1015 treatment (n=5) significantly 
decreased dopamine formation confirming L-DOPA conversion to dopamine via AADC 
(control mean 953±142.3 nmol/L vs. NSD-1015 treated mean 135±34.8 nmol/L; p<0.01). In 
contrast to dopamine metabolism, 5-HIAA was detectable in the cell culture medium and 
did not require addition of a precursor. 
Rotenone was used to model of complex I deficiency. A concentration of 100 nM was used 
as this has recently been demonstrated by our group to create an approximate 50% loss of 
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complex I activity in SH-SY5Y cells (Aylett et al., 2013). Although 3-OMD and dopamine 
concentrations were unaffected by rotenone treatment [Fig 2], a significant increase in the 
concentration of DOPAC was observed [Fig 2]. On the contrary, HVA was significantly lower 
when compared with the control cells [Fig 2]. Concerning serotonin, 5-HIAA was also 
significantly increased in the cell culture medium of the rotenone treated cells [Fig 2]. 
Treatment of the cells with CBE resulted in abolition of GBA1 activity (control = 280 
nmol/hr/mg of protein vs CBE treated = 2 nmol/hr/mg protein). GBA1 inhibition, similarly to 
rotenone, resulted in a significant decrease in HVA and a significant increase in 5-HIAA 
compared with control cells [Fig 2]. However, GBA1 inhibition led to a significantly lower 
concentration of 3-OMD compared with complex I inhibition and a marked elevation in 
DOPAC compared with both controls and complex I inhibition [Fig 2]. 
 
4. Discussion 
PD is a neurodegenerative condition affecting dopaminergic and serotonergic systems 
(Dauer and Przedborski, 2003; Olivola et al., 2014). In view of this and the evidence for 
compromised mitochondrial and lysosomal function in PD, we studied the effects of loss of 
complex I or GBA1 activity on dopamine and serotonin turnover. To achieve this we 
analysed the cell culture medium bathing SH-SY5Y cells neural cell line derived from 
neuroblastoma that has been widely used in PD studies (Hong-rong et al., 2010; Khwanraj et 
al., 2015; Lopes et al., 2010). Cell culture medium was considered as a potential means for 
rapid assessment of cellular dopamine and serotonin turnover, i.e. analogous to the use of 
CSF to evaluate CNS dopamine and serotonin metabolism (Kurian et al., 2011).   
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Although SH-SY5Y cells have the potential to become dopaminergic, this cell line does not 
synthesise or store appreciable amounts of intracellular dopamine under basal conditions 
(Balasooriya and Wimalasena, 2007). This is also reflected here by the lack of detectable 
extracellular dopamine, DOPAC and HVA in cells not incubated with L-DOPA. However, as 
expected, provision of L-DOPA resulted in an AADC-dependent appearance of dopamine and 
its metabolites in the extracellular medium. In contrast, endogenous serotonin metabolism 
appeared able to proceed, as evidenced by the detection of 5-HIAA in the cell culture 
medium. This suggests that serotonin precursors are available under basal conditions and is 
consistent with the reported ability of these cells to synthesise serotonin (Islahudin et al., 
2014).   
In order to model the partial complex I deficiency reported in PD, cells were pre-treated 
with the established complex I inhibitor, rotenone. Using this approach, complex I inhibition 
had no effect on levels of dopamine or 3-OMD. This suggests that rotenone is not having 
generalised effects resulting, e.g. from loss of cell viability, in non-specific discharge of 
cellular contents into the extracellular medium. However, when considering dopamine 
metabolites, DOPAC was significantly increased and HVA decreased. Whilst the mechanism 
for this differential effect is not known, inspection of the metabolic pathway for dopamine 
[Fig 1] could point to an increase in MAO activity and/or a reduction in COMT activity. 
Further insight into the potential mechanism may come by considering the serotonin 
metabolite, 5-HIAA. In rotenone treated cells, this metabolite was significantly elevated. 
Formation of 5-HIAA also occurs via MAO activity. Although further work is clearly required 
to ascertain whether these findings are occurring as a result of increased MAO activity, this 
suggestion is supported by the report of increased MAO activity in post mortem PD brain 
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and intracellular studies following rotenone treatment (Birkmayer et al., 1975; Sai et al., 
2008). 
MAO is located in the outer mitochondrial membrane and exists in two isoforms, MAO-A 
and MAO-B (Youdim and Bakhle, 2006). Whilst the different isoforms have different abilities 
to act upon substrates, there is overlap (Youdim and Bakhle, 2006). When considering MAO 
activity, it is important to note that a by-product of its activity is formation of hydrogen 
peroxide. Generation of the latter, in the presence of transition metals, such as iron, can 
generate highly oxidising species such as the hydroxyl radical [Fig 3]. This is of interest as 
iron is also reported to accumulate within the brain of PD patients (Riederer et al., 1989). 
Thus increased MAO activity may contribute to the oxidative stress observed in PD. 
However, further research is required to explain why such an increase might occur and, as 
implied here, in response to loss of complex I activity. 
Within neuronal cells, complex I activity may exert particular control over mitochondrial ATP 
generation (Davey et al., 1998). Thus the loss of complex I, as created here, may limit 
neuronal ATP availability. Since loading of monoamines, such as dopamine, into vesicles via 
VMAT2, is ATP dependent (Chaudhry et al., 2008), it is possible that this process could be 
compromised [Fig 3]. This is supported by reports of impaired intracellular VMAT2 activity in 
rotenone treated cells (Watabe and Nakaki, 2008). Whilst a scenario whereby dopamine is 
prevented from entering vesicles could explain increased DOPAC formation, the observed 
decreased HVA concentration requires explanation. Studies on the effects of complex I 
inhibition on COMT activity are therefore required, particularly as CSF HVA levels are 
reported to be decreased in PD  and Gaucher patients (Hartikainen et al., 1992). 
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In view of the fact that assessment of extracellular media may provide reliable insight into 
dopamine and serotonin metabolism this approach was extended to the evaluation of a 
GBA1 deficiency. CBE has been extensively used to model Gaucher disease (Cleeter et al., 
2013; Noelker et al., 2015; Ridley et al., 2013). Using this inhibitor, our findings again point 
to increased dopamine and serotonin catabolism. As for rotenone above, the lack of any 
significant effect upon dopamine release suggests that CBE is also not causing generalised 
release of intracellular contents. Concerning the mechanism for the observed increased 
dopamine and serotonin catabolism, this is not known. Loss of mitochondrial respiratory 
chain function has been reported in both CBE treated SH-SY5Y cells and in a GBA1 deficient 
animal model (Cleeter et al., 2013; Manning-Bog et al., 2009; Osellame et al., 2013). In view 
of these reports and the comparable results between rotenone and CBE treated cells, 
further work is required to ascertain whether the CBE effects are occurring via secondary 
alterations in mitochondrial function. The finding that DOPAC levels achieved in the CBE 
model were markedly greater and 3-OMD lower to those observed with rotenone could 
point to additional mechanisms. Concerning this point, it should be noted that whilst CBE is 
a documented inhibitor of GBA1, off target effects have been reported (Ridley et al., 2013). 
These will also need to be considered with regards to identifying the mechanism(s) 
responsible for the results reported here. 
 
5. Conclusion 
We have created a model system to interrogate cellular dopamine and serotonin 
metabolism by assessment of extracellular media. Our results support previous intracellular 
findings around the use of rotenone to model PD and suggest the need to further consider 
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the potential role of MAO and serotonin in disease pathogenesis. Expanding the study to the 
potential link between GBA1 deficiency and PD, evidence has been provided to also 
implicate disruption of dopamine/serotonin and homeostasis. Finally, use of extracellular 
media could enable screening of potential therapeutic agents that are targeted to correct 






Figure 1: Dopamine and serotonin pathways. Synthesis of dopamine is catalysed by tyrosine 
hydroxylase (TH) and the cofactor tetrahydrobiopterin (BH4), producing L-
dihydroxyphenylalanine (L-DOPA). L-DOPA is then transformed to dopamine by the aromatic 
L-amino acid decarboxylase (AADC) and its cofactor pyridoxal phosphate (PLP). Alternatively, 
L-DOPA can be transformed to 3-O-methyldopa (3-OMD) by catechol-O-methyl transferase 
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(COMT). Dopamine can be then catabolised by two pathways. In the first route, 3,4-
dihydroxyphenylacetic acid (DOPAC) is produced by the serial action of monoamine oxidase 
(MAO) and aldehyde dehydrogenase (ALDH); to be further metabolised by COMT to produce 
the final product of the pathway, homovanillic acid (HVA). In the second route, dopamine is 
first metabolized by COMT, producing 3-methoxytyramine (3-MT). Then, 3-MT is 
transformed to HVA by MAO and ALDH. Serotonin pathway starts with the production of 5-
hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), which also belongs to the 
BH4-dependent family. 5-HTP is transformed to serotonin by AADC and PLP. Finally, it is 
metabolised by MAO and ALDH producing 5-hydroxyindoleacetic acid (5-HIAA). 
 
 
COLOR Figure 2: Release of dopamine and metabolites to the culture media by SH-SY5Y cells 
with impaired complex I and GBA1. Cells were treated with 100 nM rotenone for 24 hours to 
model complex I impairment (n=14). Separately, 100 μM CBE treatment was carried out for 
one week to model GBA1 deficiency (n=9). In both cases, along with control (n=16), cells 
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were treated with L-DOPA 100 μM for 1 hour on day 7 after seeding. Results are expressed 
as mean ± SEM; and statistics were determined by ANOVA followed by a Tukey’s test 
(*p<0.05; **p<0.01; ***p<0.001). 
 
 
COLOR Figure 3:  Potential pathogenic mechanisms in PD. Impairment of the electron 
transport chain (ETC) might lead to an ATP deficient state and increased generation of ROS.  
Lower levels of ATP could result in dopamine accumulation in the cytosol, as dopamine 
internalisation into vesicles is an energy-dependent event (Chaudhry et al., 2008). This 
increase in cytosolic dopamine can then be then either catabolized (MAO) or autooxidised. 
The catabolism produces hydrogen peroxide (H2O2) that, in presence of metals, produces 
reactive oxygen species (ROS) that oxidize several cellular components (Aguirre et al., 2012). 
On the other hand, it has been described that autoxidation products, such as aminochrome, 
can damage complex I and stabilize alpha-synuclein (Aguirre et al., 2012; Munoz et al., 
2012). Alpha-synuclein accumulation has been proposed to enhance dopamine leaking from 
vesicles, reinforcing the presence of dopamine in the cytosol (Beyer, 2007). As the most 
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common genetic risk factor in PD is lysosomal glucocerebrosidase (GBA1) mutation 
(Neumann et al., 2009), it has been proposed that the link between GBA1 and PD is alpha-
synuclein. This is because decreased GBA1 activity reinforces alpha-synuclein accumulation 
(Mazzulli et al., 2011). Additionally loss of GBA1 may lead to a failure of mitophagy, further 
ROS production and contribute further to loss of mitochondrial function. It has also been 
described that enhanced nitric oxide synthase (NOS) activity, which produces nitric oxide 
(NO) along with other reactive nitrogen species (RNS), can ultimately inhibit the ETC 
(Bolanos et al., 1994), intensifying the ATP deficiency status. Both ROS and RNS increase the 
oxidative stress which, in healthy patients, is countered by antioxidant molecules such as 
reduced glutathione (GSH). However, GSH levels are decreased in PD brains (Sian et al., 
1994). All this events would be jointly increasing oxidative stress leading to the 
dopaminergic neurodegeneration characteristic in PD. 
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